Can nanostructured microelectrodes be used to analyze biomarkers? An interview with Dr Shana Kelley

Dr. Shana KelleyTHOUGHT LEADERS SERIES...insight from the world’s leading experts

Interview conducted by April Cashin-Garbutt, MA (Cantab)

Why have electrochemical methods to provide low cost and direct biomarker read-outs failed to provide clinically-relevant sensitivity to date?

Electrochemical methods are appealing because simple and inexpensive instrumentation can be used to make highly sensitive measurements.  However, it has been quite difficult to realize clinically-relevant levels of sensitivity using electrochemistry in highly complex, real-world samples.

Sensors at the Nanoscale from AZoNetwork on Vimeo.

The challenge relates to having a small population of a target biomarker bind to a sensor and give off a specific signal.  Usually the small number of molecules of interest are outnumbered by the billions of other molecules present in a sample.

Can you explain how you have exploited controlled nanostructuring of electrode surfaces to solve this long-standing problem?

We have created three-dimensional, large surface area electrochemical sensors that are able to sample much larger volumes of solution, so they have a much higher probability of finding low levels of a target molecule.

We’ve found that these sensors are much more effective if we create a layer of nanostructures on their surfaces.

It appears that the nanostructuring allows the probe molecules that we use for specific capture to be displayed in a more favorable and active conformation, which means that if a target molecule collides with the sensor, it has a much higher probability of binding.

Nanostructured microelectrodes to analyze biomarkers

How did you show that the nanoscale morphologies of electrode surfaces control their sensitivities?

We created sensors with similar surface areas, but with varied levels of nanostructuring.

We compared sensors that were essentially flat at the nanoscale/molecular length scale with others that had 20 nm features on their surfaces. These sensors with the nanotexturing displayed much higher levels of sensitivity.

Can you please outline your upcoming talk at Pittcon 2016?

I’ll describe the development of these sensors, our studies of how controlled surface nanostructuring influences detection sensitivity, and the applications we have pursued using these sensors to look at biological targets that are important for oncology, infectious disease management, and transplant medicine.

What Pittcon Can do for You from AZoNetwork on Vimeo.

What tests do you hope will be developed from using these components to detect markers in clinical samples?

The first area where we think these sensors will make an impact is in infectious disease testing.  Our approach provides rapid turnaround, with a test result returned within 20 minutes.

This is an important time frame for infectious disease management, as it allows physicians to test-and-treat within a single office visit.

Do you think this will impact transplant medicine?

Definitely.  It turns out that rapid testing of target biomarkers is also important for the assessment of donated organs.

Looking at donated tissue at the molecular level can give transplant surgeons a more accurate assessment of whether the organ will do well in a recipient, but there is typically a window of only a few hours where this type of information can be used to guide decision making.  So having a rapid method for biomarker analysis could also make a significant impact in this area.

What do you think the future holds for using nanostructured microelectrodes to analyze biomarkers?

We think that the application of these sensors to unmet needs in medicine will be very powerful.   The number of proof-of-concept studies that we’ve been able to do with this one sensor platform indicates that it is broadly applicable and has the potential to be used in many different areas of medicine.

Where can readers find more information?

  • www.kelleylaboratory.com
  • "Disease Detectors." S.O. Kelley, Scientific American, 2015, 313, 49-51. link
  • “Advancing the Speed, Sensitivity and Accuracy of Biomolecular Detection with Multi-Length Scale Engineering.” S.O. Kelley, C.A. Mirkin, D.R. Walt, R.F. Ismagilov, M. Toner, E.H. Sargent, Nature Nanotechnol., 2014, 9, 969-980. link
  • "Ultrasensitive Electrochemical Biomolecular Detection using Nanostructured Microelectrodes." A.T. Sage, J.D. Besant, B. Lam, E.H. Sargent, S.O. Kelley, Acc. Chem. Res., 2014, 47, 2417-2425. link
  • "Programming the Detection Limits of Biosensors through Controlled Nanostructuring. "  L. Soleymani, Z. Fang, E.H. Sargent, S.O. Kelley, Nature Nanotechnol., 2009, 4, 844.link

About Dr Shana KelleyDr Shana Kelley

Dr. Shana Kelley is a Distinguished Professor of Pharmaceutical Sciences, Chemistry, Biochemistry, and Biomedical Engineering at the University of Toronto.  Dr. Kelley received her Ph.D. from the California Institute of Technology and was a NIH postdoctoral fellow at the Scripps Research Institute.

The Kelley research group works in a variety of areas spanning bioanalytical chemistry, chemical biology and nanotechnology. Shana’s group has developed novel electrochemical sensors that enable ultrasensitive nucleic acids detection for clinical diagnostics, and has also investigated a new set of chemical probes that interact with intracellular nucleic acids.  The Kelley labs also use nucleic acids as building blocks for complex nanomaterials assembly.

Dr. Kelley’s work has been recognized with a variety of distinctions, including being named one of “Canada’s Top 40 under 40”, a NSERC E.W.R. Steacie Fellow, and the 2011 Steacie Prize. She has also been recognized with the Pittsburgh Conference Achievement Award, an Alfred P. Sloan Research Fellowship, a Camille Dreyfus Teacher-Scholar award, a NSF CAREER Award, a Dreyfus New Faculty Award, and was also named a “Top 100 Innovator” by MIT’s Technology Review.  She is a founder of two molecular diagnostics companies, GeneOhm Sciences (acquired by Becton Dickinson in 2005) and Xagenic Inc.

About Pittcon

Pittcon® is a registered trademark of The Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, a Pennsylvania non-profit organization. Co-sponsored by the Spectroscopy Society of Pittsburgh and the Society for Analytical Chemists of Pittsburgh, Pittcon is the premier annual conference and exposition on laboratory science.

Proceeds from Pittcon fund science education and outreach at all levels, kindergarten through adult. Pittcon donates more than a million dollars a year to provide financial and administrative support for various science outreach activities including science equipment grants, research grants, scholarships and internships for students, awards to teachers and professors, and grants to public science centers, libraries and museums.

Visit pittcon.org for more information.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Using spherical nucleic acids to track and treat disease